Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 172,916,816
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.80
  • Price/Sales 4.35
  • Price/Cash Flow 10.93
  • Price/Book 4.36

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.88 +1.00%
on 10/17/17
66.31 -4.22%
on 09/20/17
-2.48 (-3.76%)
since 09/18/17
3-Month
61.16 +3.84%
on 08/18/17
66.41 -4.37%
on 09/18/17
+1.10 (+1.76%)
since 07/18/17
52-Week
58.29 +8.96%
on 11/03/16
66.80 -4.93%
on 03/01/17
+1.42 (+2.29%)
since 10/18/16

Most Recent Stories

More News
What to Expect from Big Pharmas After J&J's Solid Q3 Results?

Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

JNJ : 140.68 (-0.08%)
MRK : 63.51 (+0.46%)
LLY : 85.73 (-0.38%)
NVS : 86.04 (-0.35%)
PFE : 35.83 (-1.02%)
GSK : 41.01 (+0.44%)
BMY : 63.70 (-0.75%)
U.S. FDA Accepts Regulatory Submission for LYNPARZA(R) (olaparib) in Metastatic Breast Cancer and Grants Priority Review

--Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer

MRK : 63.51 (+0.46%)
Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

Not intended for US/UK based media

MRK : 63.51 (+0.46%)
Merck's KEYTRUDA(R) (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1

--Findings from KEYNOTE-024 to Be Presented at World Conference on Lung Cancer

MRK : 63.51 (+0.46%)
Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

DARMSTADT, Germany, October 18, 2017 /PRNewswire/ --

MRK : 63.51 (+0.46%)
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

JNJ : 140.68 (-0.08%)
MRK : 63.51 (+0.46%)
ABBV : 96.04 (+4.20%)
PFE : 35.83 (-1.02%)
Bristol-Myers Gets Priority Review for Opdivo Label Expansion

Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

AZN : 34.65 (-0.37%)
NVO : 50.13 (+1.66%)
MRK : 63.51 (+0.46%)
BMY : 63.70 (-0.75%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-0.71%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.51 (+0.46%)
MDCO : 34.54 (-0.09%)
LLY : 85.73 (-0.38%)
MTZPY : 23.0400 (+1.45%)
BMY : 63.70 (-0.75%)
MKKGY : 22.2750 (-0.47%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-0.71%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.51 (+0.46%)
MDCO : 34.54 (-0.09%)
LLY : 85.73 (-0.38%)
MTZPY : 23.0400 (+1.45%)
BMY : 63.70 (-0.75%)
MKKGY : 22.2750 (-0.47%)
Cancer Space Update: Lung & Breast Cancer Studies in Focus

While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

AZN : 34.65 (-0.37%)
MRK : 63.51 (+0.46%)
LLY : 85.73 (-0.38%)
CLVS : 78.72 (-3.20%)
ABBV : 96.04 (+4.20%)
SGEN : 63.68 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 64.38
1st Resistance Point 63.94
Last Price 63.51
1st Support Level 63.24
2nd Support Level 62.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart